Adult-Onset Still´s DiseasePhase 2CONSIDERNCT02204293
Canakinumab for Treatment of Adult-onset Still's Disease
A Phase 2 study testing Canakinumab in people with Adult-Onset Still´s Disease, run by Charite University, Berlin, Germany at 14 sites in Germany.
Trial summary
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Adult-Onset Still´s Disease
- What is being tested?
- Canakinumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 14 sitesGermany
- Study dates
- 21 Jun 2012to 5 May 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written and signed consent from the participant to take part in the study
- Men and women aged ≥ 18 years and ≤ 75 years
- Fulfilment of AOSD classification criteria (according to Yamaguchi et al, J. Rheumatology, 1992)
- Disease activity based on Disease Activity Score 28 (DAS28) of ≥3.2 at screening
- At least 4 painful and 4 swollen joints at screening and baseline (of the 28 joints according to DAS28)
- If undergoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable dose for at least 4 weeks prior to randomisation
Show all 10Show fewer
- If undergoing treatment with glucocorticoids, stable dose of ≤10 milligrams per day (mg/day) (prednisolone or equivalent) for at least 4 weeks prior to randomisation
- If undergoing treatment with conventional disease-modifying anti-rheumatic drugs (DMARD), stable dose for at least 3 months prior to randomisation
- Normalisation period for biological DMARDS (anakinra 1 week, etanercept 1 month, adalimumab and certolizumab 2 months, infliximab, golimumab, abatacept and tocilizumab 3 months, rituximab 9 months, canakinumab 6 months) prior to randomisation
- In participants of reproductive age, use of an effective method of contraception as well as negative pregnancy test prior to the study commencing.
Who cannot join
- Previous treatment with the study drug with repeated administration of canakinumab
- Intraarticular or intravenous administration of glucocorticoids within 4 weeks prior to the baseline or use of narcotic analgesics except for analgesics permitted within the framework of the investigation (codeine and tramadol)
- Presence of another, serious chronic-inflammatory disease
- Positive hepatitis B antigen (HBsAg), hepatitis C antibodies and/or human immunodeficiency virus (HIV) antibodies.
- Presence of a relevant, active infection or other diseases, which entail a tendency towards infection
- Positive screening for latent tuberculosis, in accordance with usual local practice
Show all 19Show fewer
- Raised liver count (raised bilirubin; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3-fold the normal range)
- Serum-creatinine concentration >1.5 milligrams per deciliter (mg/dL)
- Inadequate haematological findings (hemoglobin [Hb] ≤ 10 grams per deciliter (g/dL), neutrophils ≤2,500/microliter (µl) and thrombocytes ≤100,000/µl)
- Simultaneous participation in any other interventional clinical study within the last 30 days preceding the commencement of the study
- History of neoplasia with the exception of a curatively treated non-melanoma skin tumour or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years
- Relevant cardiac or pulmonary disorders
- Severe intercurrent neurological or psychiatric disorders
- Macrophage activation syndrome (MAS) as part of previous treatment with IL-1 blockade (e.g. anakinra, rilonacept)
- Vaccination with a live vaccine within 3 months before the baseline
- Alcohol or drug abuse in the past 12 months
- ≥400 milliliter (mL) donation of blood or loss up to 8 weeks before the baseline
- Pregnancy or breast-feeding
- Commitment of the patient to an institution at the direction of an authority or court
Trial locations and contacts
14 sites in 1 country.
14 sites in 1 country
Germany14 sites
Charité Campus Mitte
Berlin, 10117
Immanuel Krankenhaus Berlin
Berlin, 13125
Med. Klinik I für Innere Medizin Köln
Cologne, 50937
Universität Erlangen
Erlangen, 91054
Kliniken Essen-Süd/Krankenhaus St. Josef
Essen, 45239
Universitätsklinikum der J.W. Goethe-Universität Frankfurt
Frankfurt A. M., 60590
Asklepios Klinikum Hamburg Altona
Hamburg, 22763
Medizinische Hochschule Hannover
Hanover, 30625
Universitätsklinikum Heidelberg
Heidelberg, 69120
Universitätskrankenhaus Schleswig Holstein
Kiel, 24105
Klinikum der Universität München
München, 80336
Klinikum Südstadt Rostock
Rostock, 18059
Universitätsklinikum Tübingen
Tübingen, 72076
Fachkrankenhaus
Vogelsang, 39245
About this study
Official title: Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
- Conditions
- Adult-Onset Still´s Disease
- Being tested
- Canakinumab, Placebo
- Keywords
- Adult-Onset Still´s Disease, Canakinumab, Joint involvement, AOSD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CanakinumabDrug
Also called Ilaris
Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
PlaceboDrug
Matching placebo administered subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| Canakinumab | Experimental | Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27. Receives: Drug: Canakinumab |
| Placebo | Placebo comparator | Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27. Receives: Drug: Canakinumab; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Core Study Part I: Percentage of Responders as Assessed by Disease Activity Score 28 Joints (DAS28) Score at Week 12
Responders included participants with change in disease activity score based on 28 joint counts and ESR (DAS28) score > 1.2. The DAS28 score index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and the erythrocyte sedimentation rate (ESR) value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission.
Measured: Week 12
Secondary outcomes (26)
Core Study Part I: Change From Baseline (CFB) in Disease Activity Score 28 Joints Erythrocyte Sedimentation Rate (DAS28 [ESR]) Score
The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and ESR value.Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Least squares (LS) mean was calculated by mixed linear model for repeated measures (MMRM) analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in DAS28 C-reactive Protein (CRP) Score
The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and CRP value. Total score ranged between 0-10. A DAS28-CRP score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in American College of Rheumatology (ACR) Component: 68 Tender Joint Count (TJC)
The 68 TJC included the 8 distal interphalangeal (IP), 10 proximal IP and 10 metacarpophalangeal (MTP) joints of hands, the 10 MTP and 10 proximal IP joints of feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 temporomandibular, 2 hip, 2 knee, 2 talo-tibial, and 2 mid-tarsal joints. Joint tenderness was graded present (1) or absent (0). Total score is calculated by adding the scores, which range from 0 (no tender joint) to 68 (all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: 66 Swollen Joint Count (SJC)
The 66 SJC included the 8 distal interphalangeal (IP), 10 proximal IP and 10 metacarpophalangeal (MTP) joints of hands, the 10 MTP and 10 proximal IP joints of feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 temporomandibular, 2 knee, 2 talo-tibial, and 2 mid-tarsal joints. Swelling was graded present (1) or absent (0). Total score is calculated by adding the scores, which range from 0 (no swollen joint) to 66 (all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. A negative change in Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in the 28 TJC
A total of 28 joints were assessed for tenderness. The number of tender joints could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in the 28 SJC
A total of 28 joints were assessed for swelling. The number of swollen joints could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Acute Phase Reactant CRP
A negative change from Baseline in CRP level indicates an improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Acute Phase Reactant ESR
A negative change from Baseline in ESR level indicates an improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in Serum Ferritin Level at Week 12
LS mean was calculated by MMRM analyses.
Measured: Week 12
Core Study Part I: Percentage of Responders With Fever Episodes
Fever is defined as an oral or rectal body temperature greater than 38 degrees Celsius (°C).
Measured: Week 12
Core Study Part I: CFB in ACR Component: Physician's Global Assessment of Disease Activity Score
The physician's global assessment of disease activity was assessed using a numerical rating scale of 0-10 where 0= no disease activity and 10= activity to maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Disease Activity Score
The participant's global assessment of disease activity was assessed using a numerical rating scale of 0-10, where 0= no disease activity and 10= maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Pain Score
The participant's global assessment of pain was assessed using a numerical rating scale of 0-10, where 0= no disease activity and 10= maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ measures physical disability and functional status. It has 4 dimensions: disability, pain, drug side effects and dollar costs. The HAQ score is calculated by summing the computed scores for each category and dividing by the number of categories answered. It ranges from 0 (without any difficulty) to 3 (unable to do). A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With American College of Rheumatology Response of 20 (ACR20)
ACR20 response was defined as a ≥ 20% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR30
ACR30 response was defined as a ≥ 30% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With Modified ACR30
A participant was considered responder if he/she had achieved the incidence of modified adapted response (ACR30 criteria) of at least a 30% improvement in no intermittent fever and had at least 30% improvement in at least 6 of the following 7 measures: tender and swollen 68-joint counts, participant's assessment of pain, participant's global assessment of disease activity, physician's global assessment of disease activity, participant's functional capacity (HAQ-DI score) and acute phase reactant- ESR. Participant were modified ACR30 responders at a given post-randomization visit if they satisfied the modified ACR30 criteria, respectively.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR50
ACR50 response was defined as a ≥ 50% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR70
ACR70 response was defined as a ≥ 70% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR90
ACR90 response was defined as a ≥ 90% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders With European League Against Rheumatism (EULAR) Response
EULAR response is based on DAS28-ESR and DAS28-CRP scores. The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, subject global assessment of disease activity score, and ESR or CRP value. A DAS28-CRP or ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. EULAR response has 3 categories: EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline < -1.2. EULAR Moderate response: DAS28 >3.2 to ≤ 5.1 or a change from Baseline < -0.6 to ≥ -1.2 or EULAR No response: DAS28 >5.1 or a change from Baseline < -0.6 to ≤ -1.2.
Measured: Baseline, Week 12
Core Study Part I: Percentage of Responders Achieving Low Disease Activity (LDA)
Percentage of responders were defined as the participants who achieved LDA (DAS28 score < 3.2) at Week 12. The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and ESR or CRP value. Total score ranged between 0-10. A DAS28 score greater than 5.1 implies high disease activity, equal to or less than 3.2 low disease activity, and less than 2.6 remissions.
Measured: Week 12
Core Study Part I: Percentage of Responders Achieving Disease Remission and Extended Disease Remission
Participants with disease remission: LDA (DAS28 score< 2.6). The DAS28 index is a composite score of weighted components including both 28 TJC an SJC, participant global assessment of disease activity score, and ESR or CRP value. A DAS28 score greater than 5.1: high disease activity, ≤ 3.2: low disease activity, and less than 2.6: remission. Extended remission criteria included DAS28 < 2.6 and no signs of systemic activity for up to two consecutive study visits till Week 12 defined as any of Yamaguchi´s primary classification criteria for AOSD which included fever attacks at 39 °C for more than a week, arthralgia, salmon red, maculate, urticarial or maculo-papular rash and leukocytosis (white blood cells increase) of > 10000/cubic millimeters (mm^3) with > 80% neutrophils.
Measured: Week 12
Core Study Part I: Change in Joint Mobility (Degrees of Motion) Assessed by Neutral Zero Method
Number of joints with limitation of motion according to neutral zero method was assessed which included mobility of joints (elbows, wrists, shoulder joints, hip joints, knee joints, and upper ankle joints) within the reference range/degree. Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from Baseline. A negative change score indicates improvement. LS mean was calculated by MMRM analyses.
Measured: Baseline, Week 12
Core Study Part I: CFB in Medical Outcome Short Form (SF-36) Health Survey Score
The SF-36 determines overall quality of life assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 contribute to physical component summary score (PCS). Items 5-8 contribute to mental component summary score (MCS). Scores on each item are summed and averaged (range = 0 "worst"-100 "best"). Positive numbers indicate improvement from Baseline. LS mean was calculated by MMRM analyses.
Measured: Baseline, Week 12
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. AEs include symptoms of illnesses, as well as every unfavourable and unintended reaction. SAEs are AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.
Measured: Up to Month 27
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2014 (estimated)
- Study start21 Jun 2012
- Primary completion5 May 2018
- Study completion5 May 2018
Why it stopped: Recruitment issues due to marketing authorization of study drug
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Adult-Onset Still´s DiseaseStudies of the same condition, open and under way.
- More trials run by Charite University, Berlin, GermanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Charite University, Berlin, Germany
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eugen Feist, Charite University, Berlin, Germany
- Investigators
- Eugen Feist, Prof. Dr., Principal investigator, Charité University Berlin Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02204293
- Sponsor's protocol ID
- CACZ885GDE01T
- Other IDs
- 2011-001027-20
- Acronym
- CONSIDER
- Status last verified
- Jul 2020
- First submitted
- 29 Jul 2014
- Last updated
- 7 Aug 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, Zernicke J, Martini A, Junge G. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015 Nov 20;13:50. doi: 10.1186/s12969-015-0047-3.
PubMed 26589963
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
- ClinicalTrials.gov ID
- NCT02204293
- Acronym / sponsor ID
- CONSIDER / CACZ885GDE01T
- Conditions
- Adult-Onset Still´s Disease
- Keywords
- Adult-Onset Still´s Disease, Canakinumab, Joint involvement, AOSD
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Recruitment issues due to marketing authorization of study drug
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Charite University, Berlin, GermanyUniversity, hospital or other
- Study start
- 21 Jun 2012 (actual)
- Primary completion
- 5 May 2018 (actual)
- Study completion
- 5 May 2018 (actual)
- First posted
- 30 Jul 2014 (estimated)
- Results
- Posted 7 Aug 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Canakinumab | Experimental | Drug: CanakinumabParticipants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27. |
| Placebo | Placebo comparator | Drug: Canakinumab, Drug: PlaceboParticipants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Written and signed consent from the participant to take part in the study
- Men and women aged ≥ 18 years and ≤ 75 years
- Fulfilment of AOSD classification criteria (according to Yamaguchi et al, J. Rheumatology, 1992)
- Disease activity based on Disease Activity Score 28 (DAS28) of ≥3.2 at screening
- At least 4 painful and 4 swollen joints at screening and baseline (of the 28 joints according to DAS28)
Key exclusion criteria (19 listed)
- Previous treatment with the study drug with repeated administration of canakinumab
- Intraarticular or intravenous administration of glucocorticoids within 4 weeks prior to the baseline or use of narcotic analgesics except for analgesics permitted within the framework of the investigation (codeine and tramadol)
- Presence of another, serious chronic-inflammatory disease
- Positive hepatitis B antigen (HBsAg), hepatitis C antibodies and/or human immunodeficiency virus (HIV) antibodies.
- Presence of a relevant, active infection or other diseases, which entail a tendency towards infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CanakinumabAlso: IlarisCanakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously. | Drug | Canakinumab, Placebo |
| PlaceboMatching placebo administered subcutaneously. | Drug | Placebo |
Primary outcome
Core Study Part I: Percentage of Responders as Assessed by Disease Activity Score 28 Joints (DAS28) Score at Week 12
Time frame: Week 12
Responders included participants with change in disease activity score based on 28 joint counts and ESR (DAS28) score > 1.2. The DAS28 score index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and the erythrocyte sedimentation rate (ESR) value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission.
26 secondary outcomes
Core Study Part I: Change From Baseline (CFB) in Disease Activity Score 28 Joints Erythrocyte Sedimentation Rate (DAS28 [ESR]) Score
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in DAS28 C-reactive Protein (CRP) Score
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in American College of Rheumatology (ACR) Component: 68 Tender Joint Count (TJC)
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: 66 Swollen Joint Count (SJC)
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in the 28 TJC
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in the 28 SJC
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Acute Phase Reactant CRP
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Acute Phase Reactant ESR
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in Serum Ferritin Level at Week 12
Time frame: Week 12
Core Study Part I: Percentage of Responders With Fever Episodes
Time frame: Week 12
Core Study Part I: CFB in ACR Component: Physician's Global Assessment of Disease Activity Score
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Disease Activity Score
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Pain Score
Time frame: Baseline, Weeks 4, 8 and 12
Core Study Part I: CFB in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With American College of Rheumatology Response of 20 (ACR20)
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR30
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With Modified ACR30
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR50
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR70
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With ACR90
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders With European League Against Rheumatism (EULAR) Response
Time frame: Baseline, Week 12
Core Study Part I: Percentage of Responders Achieving Low Disease Activity (LDA)
Time frame: Week 12
Core Study Part I: Percentage of Responders Achieving Disease Remission and Extended Disease Remission
Time frame: Week 12
Core Study Part I: Change in Joint Mobility (Degrees of Motion) Assessed by Neutral Zero Method
Time frame: Baseline, Week 12
Core Study Part I: CFB in Medical Outcome Short Form (SF-36) Health Survey Score
Time frame: Baseline, Week 12
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to Month 27
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26589963Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, Zernicke J, Martini A, Junge G. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015 Nov 20;13:50. doi: 10.1186/s12969-015-0047-3.
- Individual participant dataSharing planned: No
Related trials for Adult-Onset Still´s Disease
Active, not recruitingObservational study
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
Still's Disease, Adult-Onset
RecruitingPhase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Still´s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eugen Feist, Prof. Dr. principal investigator
Charité University Berlin Germany
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Canakinumab in people with Adult-Onset Still´s Disease, run by Charite University, Berlin, Germany at 14 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 7 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Core Study Part I: Percentage of Responders as Assessed by Disease Activity Score 28 Joints (DAS28) Score at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02204293, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2020.